Immunogenicity of human-induced pluripotent stem cell-derived cardiomyocyte sheets

Human-induced pluripotent stem cell-derived cardiomyocyte sheets can be a life-saving intervention for patients with advanced cardiovascular disease. Administration of immunosuppressive agents to counter CD8+ T cell-triggered tissue rejection can improve treatment outcomes. Credit: Ryu Matsumoto from Juntendo University Graduate School of Medicine Human induced pluripotent stem (hiPS) cells refer to stem cells derived from adult somatic cells like blood or skin cells. hiPS-derived cardiomyocytes (hiPC-CMs) have shown promise in treating ischemic heart disease. However, their clinical application is limited by an incomplete understanding of their immunogenicity. Now, researchers from Juntendo Read More

Related posts:

  1. Stem cell-derived therapy shows promise against treatment-resistant liver cancer
  2. Stem cell therapy could be breakthrough against type 1 diabetes
  3. Tackling the hurdle of tumor formation in stem cell therapies
  4. UK issues guidelines for use of stem cell-based embryo models in research
  5. Important step forward in stem cell therapy for rare bowel disease
  6. Mesenchymal stem cell-neural progenitors beneficial for multiple sclerosis, study shows
  7. Research harnesses machine learning and imaging to give insight into stem cell behavior
  8. Creating chimeroids by mixing stem cells from different donors to create multiple cell line organoids

Leave a Reply

Your email address will not be published. Required fields are marked *